Vireo Growth (VREOF) Non-Current Debt (2021 - 2026)
Vireo Growth's (VREOF) quarterly Non-Current Debt came in at $197.3 million in Q1 2026, up 215.16% year-on-year from $62.6 million in Q1 2025, and up 54.62% quarter-over-quarter from $127.6 million in Q4 2025.
Vireo Growth (VREOF) Non-Current Debt (2021 - 2026) Analysis & Trends
Vireo Growth has disclosed Non-Current Debt across 6 years of filings, most recently posting $197.3 million for Q1 2026.
- Non-Current Debt for Q1 2026 came in at $197.3 million, up 215.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $197.3 million (up 215.16% YoY), and the FY2025 annual result was $127.6 million, up 104.82% from the prior year.
- Non-Current Debt came in at $197.3 million for Q1 2026 at Vireo Growth, up from $127.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $197.3 million in Q1 2026 to a low of $1.1 million in Q2 2024.
- The 5-year median for Non-Current Debt is $56.0 million (2023), against an average of $63.6 million.
- Across the five-year window, Non-Current Debt tumbled 91.82% in 2023 and surged 7232.02% in 2025, its largest moves.
- Vireo Growth's Non-Current Debt stood at $46.2 million in 2022, then surged by 30.21% to $60.2 million in 2023, then advanced by 3.45% to $62.3 million in 2024, then surged by 104.82% to $127.6 million in 2025, then soared by 54.62% to $197.3 million in 2026.
- The last three Non-Current Debt figures came in at $197.3 million (Q1 2026), $127.6 million (Q4 2025), and $131.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 14.02 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 3.92 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.48 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 569.60 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 197.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197.30 Mn |
| Mar 31, 2026 | 197.30 Mn |
| Dec 31, 2025 | 127.60 Mn |
| Dec 31, 2025 | 127.60 Mn |
| Sep 30, 2025 | 131.67 Mn |
| Sep 30, 2025 | 131.67 Mn |
| Jun 30, 2025 | 82.21 Mn |
| Jun 30, 2025 | 82.21 Mn |
| Mar 31, 2025 | 62.60 Mn |
| Mar 31, 2025 | 62.60 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Sep 30, 2024 | 56.83 Mn |
| Sep 30, 2024 | 56.83 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Dec 31, 2023 | 60.22 Mn |
| Dec 31, 2023 | 60.22 Mn |
| Sep 30, 2023 | 4.06 Mn |
| Sep 30, 2023 | 4.06 Mn |